Aveo Pharmaceuticals shares are surging more than 29 percent in early trading on Monday following an announcement by the company of a new partnership with EUSA Pharma granting EUSA exclusive European distribution rights for advanced renal cell carcinoma (RCC) treatment tivozanib.

Following the announcement, Benzinga had the chance to speak with AVEO CEO Michael Bailey about the new deal.

Importance Of The Deal

Bailey told Benzinga that AVEO is primarily focusing most of its efforts on North America and that the company strives to maintain exclusive rights to tivozanib in that critical market. However, global partnerships with companies like EUSA are an important part of unlocking the full value of the drug.

“This deal represents an important milestone for AVEO in the fulfillment of that overall strategy,” Bailey added.

Tivozanib Advantage

When asked about how tivozanib compares to peer treatments, Bailey explained…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common Sense. I don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!